Patents by Inventor LAURA SAUNDERS

LAURA SAUNDERS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-DLL3 antibody drug conjugates for treating cancer
    Patent number: 10137204
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: November 27, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-claudin antibodies and methods of use
    Patent number: 10053511
    Abstract: Provided herein are anti-CLDN antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: August 21, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Marianne Santaguida, Monette Aujay, Laura Saunders, David Liu, Orit Foord, Robert A. Stull, Paul Anthony Escarpe
  • SEZ6 modulators and methods of use
    Patent number: 9993566
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: June 12, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: David Liu, Deepti Rokkam, Sheila Bheddah, Javier Lopez-Molina, Laura Saunders
  • Anti-DLL3 antibody drug conjugates and methods of use
    Patent number: 9937268
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: April 10, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Methods of delivering DLL3 antibody drug conjugates
    Patent number: 9931421
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: April 3, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Methods of making DLL3 antibody drug conjugates
    Patent number: 9931420
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: April 3, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • METHODS OF DELIVERING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20180036422
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: September 1, 2017
    Publication date: February 8, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • METHODS OF MAKING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20180036421
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: September 1, 2017
    Publication date: February 8, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • Methods of delivering DLL3 antibody drug conjugates
    Patent number: 9878053
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: January 30, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • ANTI-DLL3 ANTIBODY DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20180015178
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: September 1, 2017
    Publication date: January 18, 2018
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9867887
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: January 16, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Kits containing DLL3 antibody drug conjugates
    Patent number: 9861708
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: January 9, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-DLL3 antibody drug conjugates
    Patent number: 9855343
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: January 2, 2018
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • ANTI-DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20170368195
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: September 1, 2017
    Publication date: December 28, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • ANTI SEZ6 ANTIBODIES AND METHODS OF USE
    Publication number: 20170369571
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: June 5, 2017
    Publication date: December 28, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, ROBERT A. STULL, MICHAEL TORGOV, HUI SHAO, DAVID LIU
  • NOVEL ANTI-MFI2 ANTIBODIES AND METHODS OF USE
    Publication number: 20170320960
    Abstract: Provided are novel anti-MFI2 antibodies and antibody drug conjugates, and methods of using such anti-MFI2 anti-bodies and antibody drug conjugates to treat cancer.
    Type: Application
    Filed: September 4, 2015
    Publication date: November 9, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: SAMUEL WILLIAMS, LAURA SAUNDERS, HOLGER KARSUNKY, MANDY BOONTANRART
  • KITS CONTAINING DLL3 ANTIBODY DRUG CONJUGATES
    Publication number: 20170307622
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: June 7, 2017
    Publication date: October 26, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
  • Anti-DLL3 antibody drug conjugates for treating cancer
    Patent number: 9775916
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: October 3, 2017
    Assignee: AbbVie Stemcentrx LLC
    Inventors: Robert A. Stull, Laura Saunders, Scott J. Dylla, Orit Foord, David Liu, Michael Torgov, Hui Shao
  • Anti-DPEP3 antibodies and methods of use
    Patent number: 9777071
    Abstract: Provided herein are novel anti-DPEP3 antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 3, 2017
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Laura Saunders, Deepti Rokkam, David Liu, Mandy Boontanrart
  • DLL3 MODULATORS AND METHODS OF USE
    Publication number: 20170274094
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: June 7, 2017
    Publication date: September 28, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO